Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension

OBJECTIVE: To assess the efficacy and safety of dapagliflozin, a selective sodium-glucose cotransporter 2 inhibitor, compared with placebo in patients with type 2 diabetes (T2D), documented pre-existing cardiovascular disease (CVD), and a history of hypertension. RESEARCH DESIGN AND METHODS: Patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Cefalu, William T., Leiter, Lawrence A., de Bruin, Tjerk W.A., Gause-Nilsson, Ingrid, Sugg, Jennifer, Parikh, Shamik J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2015
Materias:
Clinical Care/Education/Nutrition/Psychosocial Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831907/
https://www.ncbi.nlm.nih.gov/pubmed/25852208
http://dx.doi.org/10.2337/dc14-0315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831907/
https://www.ncbi.nlm.nih.gov/pubmed/25852208
http://dx.doi.org/10.2337/dc14-0315

Ejemplares similares